OnKure Therapeutics (OKUR) Cash & Current Investments (2020 - 2026)

OnKure Therapeutics (OKUR) has 7 years of Cash & Current Investments data on file, last reported at $192.1 million in Q1 2026.

• Quarterly Cash & Current Investments rose 98.66% year-over-year to $192.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $192.1 million (up 98.66% YoY) and the FY2025 annual result came in at $59.0 million, down 46.69% from the prior year.
• Cash & Current Investments rose to $192.1 million in Q1 2026, from $59.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $192.1 million in Q1 2026 to a low of $59.0 million in Q4 2025.
• A 5-year average of $106.7 million and a median of $101.2 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2025 — Cash & Current Investments plunged 46.69% — and 2026, when it jumped 98.66%.
• Tracing OKUR's Cash & Current Investments over 5 years: stood at $101.2 million in 2022, then advanced by 4.01% to $105.2 million in 2023, then advanced by 5.26% to $110.8 million in 2024, then sank by 46.69% to $59.0 million in 2025, then soared by 225.32% to $192.1 million in 2026.
• The last three Cash & Current Investments figures came in at $192.1 million (Q1 2026), $59.0 million (Q4 2025), and $70.3 million (Q3 2025), per Business Quant data.